Can You Take Labetalol and Losartan Together?

Yes, labetalol and losartan can be taken together. This combination is sometimes prescribed when a single medication isn’t enough to control blood pressure, and it’s not considered a dangerous pairing. However, the two drugs do overlap in certain effects, so the combination requires monitoring and isn’t typically a first-choice pairing in current guidelines.

How These Two Drugs Work Together

Labetalol and losartan lower blood pressure through different mechanisms, which is generally what you want in a combination regimen. Labetalol slows the heart rate and relaxes blood vessels by blocking both beta and alpha receptors in the cardiovascular system. Losartan works on a completely different pathway: it blocks a hormone called angiotensin II that causes blood vessels to tighten and tells the kidneys to retain sodium and water.

Because they target different systems, combining them can produce additive blood pressure lowering. That said, current guidelines from the American College of Cardiology and the American Heart Association list beta-blockers like labetalol as a later-line option rather than a first-choice medication. The four preferred first-line classes are thiazide diuretics, calcium channel blockers, ACE inhibitors, and ARBs (the class losartan belongs to). Beta-blockers are generally reserved for people who have a specific reason to take one, such as heart failure, a fast heart rate, or certain heart rhythm problems. So if you’re on both, your prescriber likely has a clinical reason for choosing labetalol specifically.

The Main Risk: Elevated Potassium

The most important overlap between these two medications is that both can raise potassium levels in the blood. Losartan does this because blocking angiotensin II reduces the signal that normally tells your body to excrete potassium. Labetalol contributes a smaller but measurable effect through its beta-blocking activity. A large study in the journal Hypertension found that ARBs like losartan were associated with a 7% increased risk of elevated potassium, while beta-blockers added a 13% increased risk. Individually, neither number is alarming, but stacking the two effects together means your potassium levels deserve attention.

High potassium (hyperkalemia) can cause muscle weakness, numbness, and in severe cases, dangerous heart rhythm changes. Most people on this combination won’t develop problems, but your doctor will typically check your potassium and kidney function with a blood test shortly after starting or adjusting either medication, then periodically thereafter. If your kidney function is already reduced, the risk is higher and monitoring becomes more important.

Blood Pressure Dropping Too Low

Because both drugs lower blood pressure through different routes, the combined effect can occasionally be stronger than expected. Symptoms of blood pressure dropping too low include dizziness when standing up, lightheadedness, fatigue, and feeling faint. This is most common when starting one of the medications or increasing the dose. Labetalol’s usual dose range is 200 to 800 mg per day, and losartan’s is 50 to 100 mg per day. Doctors often start at the lower end of these ranges when combining the two and adjust gradually.

Pregnancy Is a Critical Exception

If pregnancy is a possibility, this combination requires immediate attention. Losartan and all other ARBs are contraindicated during the second and third trimesters because they cause well-documented fetal developmental abnormalities. Labetalol, on the other hand, is one of the most commonly used blood pressure medications in pregnancy and is increasingly preferred over older options like methyldopa because of a more favorable side-effect profile for the mother. Beta-blockers as a class are considered generally safe in pregnancy, though there are some reports of reduced fetal growth.

In practice, this means women who become pregnant while on losartan are typically switched off it promptly, and labetalol often becomes the primary or sole blood pressure medication going forward.

Watch Out for Common Pain Relievers

One interaction worth knowing about involves over-the-counter NSAIDs like ibuprofen (Advil, Motrin) and naproxen (Aleve). These common pain relievers work against both labetalol and losartan in two ways. First, NSAIDs directly reduce the blood pressure-lowering effect of both medications, making your treatment less effective. Second, NSAIDs also raise potassium levels on their own, compounding the potassium risk you already carry from this combination. If you need regular pain relief while on both medications, acetaminophen (Tylenol) is generally a safer choice for blood pressure management, though it’s worth confirming with your pharmacist.

Where This Combination Fits in Treatment

The 2025 ACC/AHA guidelines recommend starting most people who need blood pressure medication on a combination of two first-line drugs, typically an ARB or ACE inhibitor paired with either a thiazide diuretic or a calcium channel blocker. For resistant hypertension, where blood pressure remains uncontrolled despite three medications, the recommended foundation is an ARB (or ACE inhibitor), a calcium channel blocker, and a diuretic together. Beta-blockers like labetalol are listed as a fourth- or fifth-line addition.

This doesn’t mean labetalol and losartan together is a bad combination. It means that if blood pressure is your only concern and you’re not yet on a diuretic or calcium channel blocker, one of those may be tried first alongside losartan before adding labetalol. But many people have additional conditions that make labetalol the right choice regardless of the general sequencing. Heart failure, rapid heart rate, or anxiety-related blood pressure spikes are all common reasons a prescriber might choose this specific pairing.

The combination is safe for most people when monitored appropriately. The key is periodic blood work to check potassium and kidney function, paying attention to dizziness or lightheadedness (especially after dose changes), and being cautious with NSAIDs.